Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investor’s dilemma: bargain opportunity or value trap?
While market timing can be an extremely profitable strategy, it has burned many investors and requires rigorous analysis - something we specialize in at StockStory. Keeping that in mind, here are two stocks poised to prove the bears wrong and one facing legitimate challenges.
One stock to sell:
Franklin BSP Realty Trust (FBRT)
One-month return: +2.4%
Operating as a specialized real estate investment trust (REIT) with roots dating back to 2012, Franklin BSP Realty Trust (NYSE: FBRT) originates and manages a diversified portfolio of commercial real estate debt investments secured by properties in the United States and abroad.
Why Do We Steer Clear of FBRT?
- Annual net interest income declines of 4.1% for the past five years show its loan book struggled during this cycle
- Net interest income is projected to tank by 5.8% over the next 12 months as its demand continues evaporating
- Earnings per share have contracted by 33.6% annually over the last four years, a headwind for returns as stock prices often echo long-term EPS performance
Franklin BSP Realty Trust’s stock price of $6.29 implies a valuation ratio of 0.4x forward P/B. Check out our free in-depth research report to learn more about why FBRT doesn’t pass our bar.
Two stocks to watch:
Dutch Bros (BROS)
One-month return: -11.2%
Started in 1992 by two brothers as a single pushcart, Dutch Bros (NYSE: BROS) is a dynamic coffee chain that’s captured the hearts of coffee enthusiasts across the United States.
Why Will BROS Outperform?
- Fast expansion of new restaurants to reach markets with few or no locations is justified by its same-store sales growth
- Same-store sales growth over the past two years shows it’s successfully drawing diners into its restaurants
- Earnings growth has trumped its peers over the last four years as its EPS has compounded at 59.7% annually
Dutch Bros is trading at $34.69 per share, or 36x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
ANI Pharmaceuticals (ANIP)
One-month return: -2.6%
With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.
Why Could ANIP Be a Winner?
- Annual revenue growth of 36.9% over the last two years was superb and indicates its market share increased during this cycle
- Free cash flow margin expanded by 35.6 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
- Returns on capital are increasing as management’s prior bets are starting to bear fruit
At $69.68 per share, ANI Pharmaceuticals trades at 7.4x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
High-quality stocks for all market conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
